Compare CNXC & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNXC | MLYS |
|---|---|---|
| Founded | 1991 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.9B |
| IPO Year | 2020 | 2023 |
| Metric | CNXC | MLYS |
|---|---|---|
| Price | $26.46 | $23.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $54.80 | $48.67 |
| AVG Volume (30 Days) | ★ 1.6M | 1.1M |
| Earning Date | 03-24-2026 | 03-12-2026 |
| Dividend Yield | ★ 5.20% | N/A |
| EPS Growth | N/A | ★ 37.43 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,825,771,000.00 | N/A |
| Revenue This Year | $5.17 | N/A |
| Revenue Next Year | $2.51 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 2.15 | N/A |
| 52 Week Low | $24.27 | $10.44 |
| 52 Week High | $62.14 | $47.65 |
| Indicator | CNXC | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 38.32 | 36.30 |
| Support Level | N/A | $12.98 |
| Resistance Level | $34.64 | $31.09 |
| Average True Range (ATR) | 2.15 | 1.56 |
| MACD | -0.47 | -0.06 |
| Stochastic Oscillator | 23.56 | 12.94 |
Concentrix Corp is a technology and services company. It designs, implements, and manages end-to-end solutions, including customer experience process optimization, technology development and design engineering, front- and back-office automation, analytics, and business transformation services. The company serves clients across multiple industry verticals, helping them manage customer engagement and operational processes throughout the customer lifecycle. The company operates in a single operating segment. It generates revenue through the provision of technology and services under contractual arrangements. Geographically, the company generates the maximum revenue from the Philippines and the rest from India, the United States, Great Britain, Germany, Canada and Other countries.
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.